Amarin Corporation plc (AMRN) |
|
1.54 -0.09 (-5.52%)
|
03-17 16:00 |
|
Open: |
1.63 |
Pre. Close: |
1.63 |
|
High:
|
1.63 |
Low:
|
1.54 |
|
Volume:
|
1,668,783 |
Market Cap:
|
625(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 8:44:02 AM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.21 One year: 2.53 |
| Support: |
Support1: 1.46 Support2: 1.21 |
| Resistance: |
Resistance1: 1.89 Resistance2: 2.17 |
| Pivot: |
1.76 |
| Moving Average: |
MA(5): 1.56 MA(20): 1.77
MA(100): 1.51  MA(250): 1.65 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 14.5 %D(3): 11.9 |
| RSI: |
RSI(14): 37.9 |
| 52-week: |
High: 3.74 Low: 1.03 |
| Average Vol(K): |
3-Month: 4,813 (K) 10-Days: 4,556 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AMRN ] has closed above bottom band by 19.0%. Bollinger Bands are 88.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.63 - 1.64 |
1.64 - 1.65 |
|
Low:
|
1.52 - 1.53 |
1.53 - 1.54 |
|
Close:
|
1.53 - 1.54 |
1.54 - 1.55 |
|
Company Description |
|
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland. |
Headline News |
Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Peter Lynch - 3/19 ... - Nasdaq
Thu, 16 Mar 2023
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl) - Yahoo Finance
Mon, 13 Mar 2023
Amarin Co. plc (NASDAQ:AMRN) Sees Large Growth in Short Interest - MarketBeat
Mon, 06 Mar 2023
Amarin touts in vitro data on omega-3 fatty acid EPA in reducing ... - Seeking Alpha
Thu, 02 Mar 2023
Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates - Nasdaq
Wed, 01 Mar 2023
2023-03-01 | NDAQ:AMRN | Press Release | Amarin Corporation plc - Stockhouse
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
406 (M) |
| Shares Float |
375 (M) |
|
% Held by Insiders
|
0.4 (%) |
|
% Held by Institutions
|
34.2 (%) |
|
Shares Short
|
14,520 (K) |
|
Shares Short P.Month
|
12,620 (K) |
Stock Financials |
|
EPS
|
-0.25 |
|
EPS Est Next Qtl
|
-0.03 |
|
EPS Est This Year
|
-0.21 |
|
EPS Est Next Year
|
-0.06 |
|
Book Value (p.s.)
|
1.47 |
|
Profit Margin (%)
|
-28.7 |
|
Operating Margin (%)
|
-20.2 |
|
Return on Assets (ttm)
|
-4.8 |
|
Return on Equity (ttm)
|
-16.8 |
|
Qtrly Rev. Growth
|
-37.5 |
|
Gross Profit (p.s.)
|
0.64 |
|
Sales Per Share
|
0.9 |
|
EBITDA (p.s.)
|
-0.18 |
|
Qtrly Earnings Growth
|
-94.2 |
|
Operating Cash Flow
|
-180 (M) |
|
Levered Free Cash Flow
|
-86 (M) |
Stock Valuations |
|
PE Ratio
|
-6.16 |
|
PEG Ratio
|
-0.4 |
|
Price to Book value
|
1.04 |
|
Price to Sales
|
1.69 |
|
Price to Cash Flow
|
-3.48 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
